Restoring the epigenome in Alzheimer's disease: Advancing HDAC inhibitors as therapeutic agents

Márcia Pereira,Maria Teresa Cruz,Ana Fortuna,Joana Bicker
DOI: https://doi.org/10.1016/j.drudis.2024.104052
IF: 8.369
2024-06-05
Drug Discovery Today
Abstract:Current treatment options for Alzheimer's disease (AD) focus on symptom relief rather than halting disease progression. In this context, targeting histone deacetylation emerges as a promising therapeutic alternative. Dysregulation of histone deacetylase (HDAC) activity is present in AD, contributing to cognitive decline. Pharmacological HDAC inhibition has shown benefits in preclinical models, namely reduced amyloid beta plaque formation, lower phosphorylation and aggregation of tau protein,...
pharmacology & pharmacy
What problem does this paper attempt to address?